MedicalCV Announces Information to Be Available Through S&P Market Access Program MINNEAPOLIS, May 2 /PRNewswire-FirstCall/ -- MedicalCV, Inc. (OTC:MDCV) (BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ , a cardiovascular surgery device manufacturer, focusing on the surgical needs surrounding atrial fibrillation, announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com/ . In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all-major quote vendors. As part of the program, a full description of MedicalCV, Inc. will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 37 states under the Blue Sky Laws. About MedicalCV, Inc. MedicalCV, Inc., a cardiovascular surgery device manufacturer, focuses on the design, development and commercialization of new, improved and enhanced technologies, products, methods and techniques to treat cardiovascular disorders and disease, including products targeting the treatment of atrial fibrillation ("AF"). Historically, MedicalCV developed and marketed Omnicarbon(R) mechanical heart valves utilizing its proprietary pyrolytic carbon processes. As of April 2005 the Company ceased marketing mechanical heart valves to focus on products for the treatment of AF. The Company's core technology is the ATRILAZE(TM) Surgical Ablation System, for use in cardiac tissue ablation in surgery, which the Company acquired on August 27, 2003 and for which it received FDA 510(k) clearance on November 30, 2004. The Company's common stock is traded on the OTC Bulletin Board under the symbol "MDCV." For further information on MedicalCV, Inc., please visit http://www.medcvinc.com/ . You may register to receive MedicalCV's future press releases and to be added to the Company's distribution list by visiting: http://www.roiny.com/form.php . Company information distributed through the Market Access Program is based upon information that Standard & Poor's considers to be reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. MedicalCV, Inc. Contact: John H. Jungbauer Vice President, Finance and CFO Phone 651.452.3000 http://www.medcvinc.com/ Investor Relations Contact: ROI Group Associates, Inc. Robert Giordano / Sarah Shepard President / Vice President Phone 212.495.0200, ext. 10 / 17 / http://www.roiny.com/ DATASOURCE: MedicalCV, Inc. CONTACT: John H. Jungbauer, Vice President, Finance and CFO of MedicalCV, Inc., +1-651-452-3000, , or Investor Relations, Robert Giordano, President, +1-212-495-0200 ext. 10, , or Sarah Shepard, Vice President, +1-212-495-0200 ext. 17, , both of ROI Group Associates, Inc. Web site: http://www.medcvinc.com/ http://www.advisorinsight.com/ http://www.roiny.com/form.php

Copyright